

[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
[ Tue, Apr 30th 2024
] - WOPRAI
Ashwani Verma Maintained (ACAD) at Strong Buy with Decreased Target to $27 on, Apr 30th, 2024
Ashwani Verma of UBS, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy with Decreased Target from $33 to $27 on, Apr 30th, 2024.
Ashwani has made no other calls on ACAD in the last 4 months.
There are 13 other peers that have a rating on ACAD. Out of the 13 peers that are also analyzing ACAD, 3 agree with Ashwani's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $30 on, Tuesday, March 12th, 2024
- Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $19 on, Tuesday, March 12th, 2024
- Uy Ear of "Mizuho" Downgraded from Strong Buy to Hold and Decreased Target to $25 on, Tuesday, March 12th, 2024
These are the ratings of the 10 analyists that currently disagree with Ashwani
- Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $32 on, Tuesday, April 9th, 2024
- Tessa Romero of "JP Morgan" Maintained at Buy with Decreased Target to $25 on, Monday, March 25th, 2024
- Jeffrey Hung of "Morgan Stanley" Maintained at Buy with Decreased Target to $30 on, Wednesday, March 13th, 2024
- Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $31 on, Tuesday, March 12th, 2024
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $33 on, Tuesday, March 12th, 2024
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $33 on, Tuesday, March 12th, 2024
- David Hoang of "Citigroup" Maintained at Strong Buy with Decreased Target to $30 on, Tuesday, March 12th, 2024
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $30 on, Tuesday, March 12th, 2024
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $39 on, Tuesday, March 12th, 2024
- Joseph Stringer of "Needham" Upgraded from Hold to Strong Buy and Held Target at $37 on, Wednesday, January 24th, 2024
Contributing Sources